Central Nervous System (CNS) Lymphoma Treatment

CNS lymphoma is a rare form of non-Hodgkin lymphoma that begins in the brain, spinal cord, eyes or the membranes surrounding these structures. Unlike other lymphomas that arise in the lymph nodes, it originates in the central nervous system and usually remains confined there at the time of diagnosis.

Although the exact cause of CNS lymphoma is unclear, scientists believe it develops when certain white blood cells (lymphocytes) grow uncontrollably within the central nervous system. This condition is common in individuals with a weakened immune system, including those with HIV/AIDS, organ transplant recipients and people who are taking immunosuppressive medications. That said, it can also occur in individuals with no known immune deficiency.

Symptoms of central nervous system lymphoma may include persistent headaches, changes in vision, difficulties with balance or coordination, memory loss, confusion, weakness, numbness or seizures. Because this type of cancer can progress quickly, prompt treatment is essential. Care is typically coordinated by a multispecialty team with expertise in both neuro-oncology and hematologic cancers. Treatment options may include:

Chemotherapy for CNS lymphoma

Chemotherapy is the cornerstone of treatment for central nervous system lymphoma. Typically, a high-dose regimen is required to penetrate the blood-brain barrier. This protective network of tightly packed cells lines the blood vessels of the brain, serving as a shield against toxins and infections. While the blood-brain barrier is essential for protecting healthy brain tissues, it also limits the ability of many standard chemotherapy drugs to reach therapeutic levels in the central nervous system, making higher doses or specially selected agents necessary for effective treatment.

Chemotherapy may be appropriate for central nervous system lymphoma if:

• The condition is newly diagnosed
• The lymphoma is confined to the central nervous system
• Rapid cancer control is needed

Rated High Performing in Leukemia, Lymphoma & Myeloma

Recognized in U.S. News & World Report's Best Hospitals for significantly better performance in leukemia, lymphoma and myeloma treatment than the national average.

Schedule an Appointment

Frequently used chemotherapy drugs and regimens include:

• High-dose methotrexate – Due to its ability to reach therapeutic levels within the central nervous system, high-dose methotrexate serves as the foundation of most CNS lymphoma treatment plans.
• Cytarabine – This potent chemotherapy agent is often combined with methotrexate for heightened effectiveness.
• Rituximab – A monoclonal antibody medication, rituximab targets CD20-positive lymphoma cells.
• Combination regimens – A common example is MATRix, which combines methotrexate, cytarabine, thiotepa and rituximab.

Chemotherapy for CNS lymphoma may be delivered intravenously, allowing the medications to circulate through the bloodstream and reach the central nervous system at high doses. It may also be delivered directly into the cerebrospinal fluid through a method known as intrathecal therapy. Intrathecal administration can enable the drugs to bypass the blood-brain barrier and reach cancer cells more directly within the brain and spinal cord. For this reason, this delivery technique may be used in certain cases to enhance treatment effectiveness or address cancer involving the cerebrospinal fluid.

Side effects of chemotherapy for central nervous system lymphoma may include fatigue, nausea, kidney or liver toxicity, low blood cell counts and an increased risk of infection. Because high-dose methotrexate is central to treatment, the patient will require close monitoring to manage the potential toxicity and ensure safe drug clearance.

Targeted therapy for CNS lymphoma

Targeted therapy is increasingly being used for central nervous system lymphoma treatment, particularly in relapsed and refractory cases. Targeted drugs are designed to interfere with the specific molecular pathways that cancer cells rely on for growth, survival and proliferation. By blocking these signals, this highly precise treatment approach can help slow cancer progression and, in some cases, shrink tumors while minimizing damage to the surrounding healthy cells.

Targeted therapy may be appropriate for central nervous system lymphoma if:

• The cancer does not respond to standard chemotherapy
• The lymphoma returns after initial treatment
• The patient cannot tolerate intensive chemotherapy

Targeted drugs that may be used for CNS lymphoma treatment include:

• Ibrutinib – A Bruton's tyrosine kinase (BTK) inhibitor that can disrupt lymphoma cell signaling
• Lenalidomide – An immunomodulatory agent with targeted anti-lymphoma effects

Side effects of targeted therapy for central nervous system lymphoma may include fatigue, diarrhea, bleeding, infection and changes in blood cell counts.

Radiation therapy for CNS lymphoma

Radiation therapy is sometimes used as a consolidation treatment for central nervous system lymphoma. Also known as post-remission therapy, this treatment is given after the initial induction therapy has successfully induced remission and the lymphoma has disappeared. It aims to destroy any remaining microscopic cancer cells—even if they are undetectable—to help prevent relapse. In select cases, radiation therapy may also be used if chemotherapy is not appropriate.

This localized treatment approach delivers focused, high-energy beams to destroy cancer cells within the brain, helping to eliminate residual lymphoma and reduce the risk of recurrence. Because CNS lymphoma often involves sensitive brain structures, radiation therapy must be carefully planned to maximize tumor control while minimizing exposure to surrounding healthy tissues.

Radiation therapy may be appropriate for central nervous system lymphoma if:

• There is concern about residual cancer after chemotherapy
• The lymphoma recurs
• The patient is not a candidate for intensive chemotherapy

Radiation delivery techniques used for CNS lymphoma include:

• Whole-brain radiation therapy (WBRT) – Delivers radiation to the entire brain, which can be effective for treating lymphoma that may be widespread or not easily localized within the central nervous system
• Intensity-modulated radiation therapy (IMRT) – Uses advanced planning technology to precisely shape and adjust the radiation beams, allowing for targeted treatment of specific areas of the brain while reducing exposure to nearby healthy tissues

Short-term side effects of radiation therapy for central nervous system lymphoma can include fatigue, hair loss and scalp irritation. Possible long-term side effects, particularly with WBRT, include cognitive changes, such as memory loss, difficulty concentrating and slower processing speed. For this reason, the healthcare team will carefully weigh the benefits and risks before recommending WBRT, especially for an older patient.

Immunotherapy for CNS lymphoma

Immunotherapy for central nervous system lymphoma is designed to help the body’s immune system recognize and attack cancer cells, either by enhancing the natural immune response or targeting specific proteins found on cancer cells. It may be used alongside other treatments or as a standalone therapy for recurrent or treatment-resistant lymphoma.

Immunotherapy may be appropriate for central nervous system lymphoma if:

• The cancer has relapsed or does not respond to standard treatments
• The patient is eligible for participation in a clinical trial

Examples of immunotherapy drugs that may be used for central nervous system lymphoma include:

• Rituximab – Commonly incorporated into chemotherapy regimens
• Immune checkpoint inhibitors – Currently under investigation in clinical trials

Side effects of immunotherapy for central nervous system lymphoma may include infusion-related reactions, fatigue and inflammation affecting various organs, such as the lungs, liver, intestines or endocrine glands.

Bone marrow transplantation (BMT) for CNS lymphoma

Following a favorable response to chemotherapy, BMT may be used as consolidation therapy for central nervous system lymphoma, particularly in a young, otherwise healthy patient who can tolerate a more intensive treatment approach. In this setting, the goal is to reinforce the initial treatment response, reduce the risk of relapse and support long-term cancer control by replacing the patient’s damaged bone marrow with healthy blood-forming cells.

A bone marrow transplant may be considered for CNS lymphoma if:

• The patient achieves remission after initial treatment
• The cancer is high-risk or recurrent
• The patient can tolerate aggressive therapy

Typically, bone marrow transplantation involves administering high-dose chemotherapy to destroy any remaining cancer cells, followed by reinfusion of the patient’s own previously collected blood-forming cells (autologous transplant) to help restore bone marrow function. Over time, the transplanted cells may travel to the bone marrow and begin producing new, healthy blood cells.

Risks of BMT include infection due to temporary immune system suppression and complications related to the marrow-ablative preconditioning regimen, such as organ toxicity and severe fatigue. Additionally, prolonged low blood cell counts may require transfusions. Because of these risks, the patient will be closely monitored throughout treatment and recovery.

Surgery for CNS lymphoma

Surgery is not a standard treatment for CNS lymphoma, mainly because the condition is typically highly responsive to chemotherapy and radiation therapy, which can effectively target cancer throughout the central nervous system. However, surgery may be performed to obtain a biopsy, allowing the physician to confirm the diagnosis and determine the specific subtype of lymphoma to guide treatment decisions.

In certain cases, surgery may also be considered to address mass effect, which is damage, compression or displacement of surrounding healthy tissues caused by the physical growth of a tumor, swelling or associated bleeding. Mass effect can cause symptoms such as severe headaches, neurological deficits and changes in consciousness. However, extensive surgical removal is generally avoided due to the diffuse nature of CNS lymphoma and the potential risks of operating within sensitive brain tissues. These risks can vary depending on the location of the surgical site and the complexity of the procedure, but may include bleeding, infection, swelling and neurological deficits, such as changes in speech, movement or cognitive function. Careful surgical planning is essential to minimize risks while achieving the intended diagnostic or therapeutic goal.

Clinical trials for CNS lymphoma

Clinical trials are an important option for certain patients with central nervous system lymphoma, particularly those with recurrent or treatment-resistant disease. These carefully designed studies evaluate new therapies and treatment strategies aimed at improving outcomes and reducing side effects. Ongoing research subjects include novel targeted agents, combination regimens and advanced immunotherapies, such as chimeric antigen receptor (CAR) T-cell therapy, which is being explored for its potential to harness the patient’s own immune cells to fight lymphoma.

Participating in a clinical trial may provide the patient with:

• Access to innovative treatments that are not yet widely available
• Close monitoring and support from a multispecialty care team
• The opportunity to contribute to advances in lymphoma care and help shape future treatment standards

Eligibility for a clinical trial is determined based on several factors, including the patient’s prior treatments and overall health, as well as the specific disease characteristics and, in some cases, its molecular or genetic features. The healthcare team can determine whether a clinical trial is an appropriate option and guide the patient through the selection and enrollment process.

Benefit from world-class care at Moffitt Cancer Center

At Moffitt, patients with CNS lymphoma can receive care from a multispecialty team with expertise in both neuro-oncology and hematology. Our specialists use advanced diagnostic tools and cutting-edge treatment approaches, including a robust portfolio of clinical trials, to develop highly individualized treatment plans. As a National Cancer Institute (NCI)-designated Comprehensive Cancer Center, Moffitt is widely recognized for excellence in research, innovation and patient-centered care.

If you would like to learn more about CNS lymphoma treatment, you can request an appointment with a specialist in the Malignant Hematology Program at Moffitt by calling 1-888-663-3488 or submitting a new patient registration form online. We do not require referrals.